No continuation candles currently present.
PROFILE: Clinuvel Pharmaceuticals (CUV.AX)
Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.
|EMH European Metals Holdings||0.4||12.9||50,755||0||NEUTRAL|
|RMS Ramelius Resources||0.5||7.5||3,500,339||0||NEUTRAL|
|BOC Bougainville Copper||0.17||6.3||61,005||0||NEUTRAL|
|RND Rand Mining||4.03||6.1||33,780||0||NEUTRAL|
|CAB Cabcharge Australia||2.4||5.7||194,554||0||NEUTRAL|
|CCV Cash Converters International||0.33||4.8||1,818,562||0||NEUTRAL|